Ginkgo Bioworks Holdings EBITDA 2020-2023 | DNA

Ginkgo Bioworks Holdings ebitda from 2020 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Ginkgo Bioworks Holdings Annual EBITDA
(Millions of US $)
2022 $-2,165
2021 $-1,799
2020 $-123
2019 $-61
Ginkgo Bioworks Holdings Quarterly EBITDA
(Millions of US $)
2023-03-31 $-197
2022-12-31 $-218
2022-09-30 $-644
2022-06-30 $-637
2022-03-31 $-666
2021-12-31 $-1,677
2021-09-30 $-18
2021-06-30 $-53
2021-03-31 $-51
2020-12-31
2020-09-30 $-34
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.379B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00